Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 1:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 12,488 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: combined therapy treatment Clear all
Completed Phase 4 Interventional Results available

Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

NCT00806234
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 19 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available

Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma

NCT01386632
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DCA (dichloroacetate), Placebo
Drug
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
Fargo, North Dakota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combined Pharmaco/Behavior Therapy in Adolescent Smokers

NCT00330187
View directory record Official record
Conditions
Nicotine Dependence, Nicotine Use Disorder
Interventions
Bupropion SR, Contingency Management, Placebo
Drug · Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

NCT00738452
View directory record Official record
Conditions
Lung Cancer
Interventions
high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, radiation therapy, yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Other · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 4 Interventional

A Study of Combination Therapy in Children With ADHD

NCT01940978
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Mental Disorders Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorders
Interventions
Methylphenidate ER, Cyproheptadine
Drug
Lead sponsor
Douglas Sears
Individual
Eligibility
6 Years to 12 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Van Nuys, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 1 Interventional Results available

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 28, 2026, 1:36 AM EDT
Completed No phase listed Observational

Trimethoprim-Sulfamethoxazole vs Levofloxacin as Targeted Therapy for Stenotrophomonas Maltophilia Infections: a Retrospective Cohort Study

NCT04639817
View directory record Official record
Conditions
Stenotrophomonas Infection
Interventions
Levofloxacin, trimethoprim-sulfamethoxazole
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
1,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 28, 2026, 1:36 AM EDT
Recruiting Not applicable Interventional

CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms

NCT05663034
View directory record Official record
Conditions
Traumatic Brain Injury, Insomnia, Depression, Post-traumatic Stress, Sleep, Memory Impairment, Cognitive Behavioral Therapy, Concussion, Brain, Head Injury, Brain Injury Traumatic Mild
Interventions
Mindfulness-based treatment for insomnia (MBTI), Cognitive behavioral therapy for insomnia (CBT-I)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Eglin Air Force Base, Florida • Bethesda, Maryland • Fort Bragg, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Not applicable Interventional

Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults

NCT00099684
View directory record Official record
Conditions
HIV Infections
Interventions
Ezetimibe
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 28, 2026, 1:36 AM EDT
Terminated Phase 3 Interventional

Phase III ALTU-135 CP Safety Trial

NCT00500084
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
Liprotamase
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
Hamden, Connecticut • Jacksonville, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment

NCT00762125
View directory record Official record
Conditions
Fibromyalgia
Interventions
CR+ST, ET, AC treatment
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 28, 2026, 1:36 AM EDT
Not listed Phase 2 Interventional

Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer

NCT00178763
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Heckel Infrared Radiant Heat Device, cisplatin, gemcitabine, interferon-alpha, thermochemotherapy
Device · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 3 Interventional

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

NCT00035321
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Olanzapine, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
30
States / cities
Oceanside, California • San Marcos, California • Torrance, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2006 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

NCT01629758
View directory record Official record
Conditions
Neoplasms by Site
Interventions
Denenicokin, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma

NCT03730363
View directory record Official record
Conditions
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Pentamidine
Drug
Lead sponsor
Reinhold Munker
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 28, 2026, 1:36 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

NCT01110421
View directory record Official record
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

NCT00002321
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 1:36 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

NCT02143414
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Biopsy Procedure, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Computed Tomography, Dasatinib, Echocardiography Test, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
65 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
195
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 139 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 28, 2026, 1:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

NCT03011814
View directory record Official record
Conditions
Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Lenalidomide
Biological · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
4
States / cities
Duarte, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

NCT02065752
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg, CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 3 Interventional

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

NCT00449878
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Liprotamase, Placebo
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 28, 2026, 1:36 AM EDT
Recruiting Early Phase 1 Interventional

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

NCT07071155
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms, Chronic Neutrophilic Leukemia
Interventions
Momelotinib, Azacitidine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 28, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

High Dose Ascorbic Acid for Plasma Cell Disorders

NCT03602235
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ascorbate, Melphalan
Other · Drug
Lead sponsor
Christopher Strouse
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 28, 2026, 1:36 AM EDT